Tech Company Financing Transactions
Oncomatryx Funding Round
On 3/30/2026, Oncomatryx raised $67 million in funding from Basque Fondo, CDTI and private investors.
Transaction Overview
Company Name
Announced On
3/30/2026
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This funding validates the clinical progress of our lead candidate OMTX705 and equips us to take OMTX105 and other Quantum ADCs into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Parque Tecnológico de Bizkaia 801B -- 2P
Derio. Bizkaia, 48160
Spain
Derio. Bizkaia, 48160
Spain
Phone
Website
Email Address
Overview
Our mission is to revolutionize Oncology, through targeted intervention in the tumor microenvironment with next-generation drugs. In our constant pursuit of patient improvement, Oncomatryx vision is to turn immune-cold into immune-hot tumors, prolong and improve the quality of life for patients suffering from metastatic solid tumors and cure cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laureano Simón
Chief Marketing Officer
Ignacio García
Chief Operating Officer
Manuel Sanz
Chief Scientific Officer
Myriam Fabre
VP - Bus. Development
David Raksin
VP - Product Management
Pedro Esnaola
Browse more venture capital transactions:
Prev: 3/30/2026: Aurora Hydrogen venture capital transaction
Next: 3/30/2026: Midas Software venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC transactions on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs